The present invention relates to the therapeutic use of CD44 inhibitor agents against human acute lymphoblastic leukaemia (ALL). Specifically, the present invention relates to an agent for inhibiting the function of CD44 for the use thereof in medicine, preferably for the prevention and/or treatment of human T-ALL, as well as to a pharmaceutical composition and to a kit. The present invention also relates to a method for preventing and/or treating human T-ALL, to a model of ICN1-induced human T-ALL pre-leukemic cells in mice, and to a xenotransplant model in mice for the study of early molecular alterations associated with the generation of cells that initiate and maintain human T-ALL.
展开▼
